Press releases

12/11/2018 07:30
|

Quantum Genomics Announces Excellent Topline Results from Phase 2b NEW-HOPE Study Evaluating Firibastat for Arterial Hypertension

25/10/2018 18:00
|

Quantum Genomics Announces Webcast Discussion of Top-line Results from its Phase 2b NEW-HOPE Study in Arterial Hypertension on November 12, 2018

18/10/2018 18:30
|

Quantum Genomics receives ethics committee approval to initiate clinical study of extended-release firibastat tablets

05/10/2018 07:30
|

Quantum Genomics to Present Top-Line Results from Phase 2b NEW-HOPE Study in Late-Breaking Presentation on November 10, 2018, at the American Heart Association meeting in Chicago

04/10/2018 18:00
|

Quantum Genomics Reports First Half Financial Results and Provides Corporate Update

17/09/2018 18:00
|

Quantum Genomics will present top line results for the NEW HOPE phase IIb hypertension study at the American Heart Association (AHA) annual meeting in Chicago (November 10-12, 2018)

06/09/2018 20:30
|

Quantum Genomics completes patient recruitment more than six months ahead of initial schedule in its phase IIb hypertension (NEW-HOPE) study, now expects to present results by mid-November 2018

26/06/2018 18:00
|

Quantum Genomics announces trial design for QUORUM, its Phase IIb study in heart failure

04/06/2018 18:00
|

FIRIBASTAT Approved as Common International Name for QGC001 by World Health Organization

19/04/2018 17:45
|

Quantum Genomics enters a new phase of maturity with its BAPAIs Fast Growth strategic plan

09/04/2018 18:00
|

Quantum Genomics strengthens its governance

29/03/2018 18:00
|

Quantum Genomics publishes its financial results for the year 2017

05/03/2018 18:30
|

Quantum Genomics Secures Operational Flexibility and Growth Capital through Equity Line Financing with Kepler Cheuvreux

05/02/2018 18:00
|

Quantum Genomics strengthens its Scientific Advisory Board with the appointment of Professor Frans Leenen, a renowned expert in congestive heart failure